Durvalumab vs Lithium Carbonate

## Durvalumab vs Lithium Carbonate: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Lithium Carbonate**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Lithium Carbonate**: Modulates intracellular signaling via inositol and GSK-3 inhibition.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Lithium Carbonate — 18-36 hours.

## Chemical Properties

**Molecular Formula**: Durvalumab — N/A; Lithium Carbonate — Li2CO3.

**Molecular Weight**: Durvalumab — N/A; Lithium Carbonate — 73.8910 g/mol.

**Type**: Durvalumab — Antibody; Lithium Carbonate — Small molecule.